Atlas
Market PulseMovers & ShakersSector ViewStocksETFFundsPortfoliosAdmin
Atlas › Stocks › SMSPHARMA

SMSPHARMA

SMS Pharmaceuticals Limited
Micro-capPharma ↗

What the six lenses say about SMSPHARMA — its relative strength vs the baselines, price & RS trend, the 8-quarter financials, and live filings.

Price
₹397.9
2026-09-08
VWAP · 1Y anchor
₹338
+17.8% from VWAP
P/E · TTM
36.1×
TTM EPS ₹11.0
52-week range
81%
position low→high
RSI(14)
67
momentum

Own sector index

Pharma ↗
Overweight

1M

+0.4%

3M

+10.5%

1Y

+22.0%

Breadth >EMA21

56%

How SMSPHARMA’s own sector index is moving — context for reading the stock’s six lenses.

Six-lens read

What the six lenses say

How the lenses are scored ↗
Strength
5.5
avg conviction decile
Leadership
—
top-decile composite in cohort
Each lens is a decile within its cap cohort (D10 = top 10%) — no black-box composite. Expand a lens for the real numbers behind it.
LensDecile · Micro-cap cohortDRaw
TechnicalD660›

The actual numbers

Price vs VWAP (1y)+17.8%
EMA trend stackMixed
Price vs 200-EMA+11.3%
Price vs 50-EMA+6.0%
RSI(14)67
RS vs Nifty 500 · 3M+3.5%
RS vs sector · 3M-2.6%
52-week range81%
Volume vs 30d avg1.89×
Volume vs 60d avg1.61×
ATR(14) · volatility18.2
Bollinger width · vol contraction0.133
FundamentalD855›

The actual numbers

Return on equity (ROE)12.9%
Operating margin15.7%
Net margin11.4%
Revenue growth · YoY+13.2%
EPS growth · YoY+36.3%
Debt / equity0.46×

Full 8-quarter history in the financials table below.

ValuationD421›

The actual numbers

P/E (TTM)36.1×
TTM EPS₹11.0
52-week range81%
CatalystD535›

The actual numbers

Earnings & momentum33
Capital actions12
Governance85

Every filing in the corporate-announcements panel below.

FlowD550›

The actual numbers

Promoter holding68.1%
Delivery · 30d avg53.3%
Up/down-day asymmetry-2.0pp
How the decile & conviction are calculated

Decile — each lens’s 0–100 score is ranked against every Micro-cap stock in the universe. D10 = top 10% (strongest), D1 = bottom 10%. A decile is simply where this stock sits versus its size-peers on that lens — no weighting, no black box.

Conviction — the average of the two active conviction-lens deciles (Technical & Flow):

( D6 + D5 ) ÷ 2 = 5.5(Technical · Flow)

Fundamental, Catalyst, Valuation and Policy are shown for context but carry weight 0 in the current model, so they are not scored into conviction. Full detail on the methodology page ↗.

Glass box

How the score is built

Click a lens to expand its sub-components, then drill to the actual values. The eye icon on any term explains it.

Conviction score · High
59
Conviction score 59/100 · avg-decile strength 5.5/10
Conviction score59/100›
TechnicalD6›
FundamentalD8›
ValuationD4›
CatalystD5›
FlowD5›

Policy

Government policy · Pharma

Active policies relevant to this sector — flagged as a Red / Amber / Green signal, not scored into the six-lens conviction. The lenses say what the market is doing; policy is context for why.

Tailwind· HIGH impact

PLI Scheme — Pharmaceuticals & API

Production-linked incentive scheme for pharmaceuticals, APIs, and medical devices

Relative strength · always on

Percentage-point spread vs each baseline across six windows. Green = outperforming, red = lagging. Data as of 2026-09-08.

Baseline1D1W1M3M6M12M
Nifty 50
Large-cap anchor
+1.9pp
+8.3pp
+14.9pp
+5.1pp
+8.7pp
+66.9pp
Nifty 500
Broad-market baseline
+1.8pp
+8.3pp
+13.8pp
+3.5pp
+2.9pp
+61.7pp
Sector
Own-sector index
—
—
+11.0pp
-2.6pp
-10.2pp
+40.9pp

From atlas_foundation.technical_daily. Sector row covers 1M–12M (1D/1W not stored).

Trend

Price · EMA 20 / 50 / 200

SMSPHARMA daily close with the three trend EMAs · atlas_foundation.ohlcv_stock.

₹ (close)
397.95+5.45

Relative strength

RS vs baseline · rebased to 100

SMSPHARMA ÷ Nifty 500, rebased to 100 at window start — above 100 = outperforming since then.

RS vs Nifty 500 (=100)
118.93+2.12

TradingView composite technical analysis — multi-timeframe consensus

Quarterly financials

Last 8 quarters from the company’s filings (₹ crore) — revenue, profit, margins and the growth trend.

MetricJun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26
Revenue (₹cr)164197173248196242210238
↳ change QoQ—+19.6%-11.9%+43.1%-21.0%+23.5%-13.2%+13.3%
EBITDA (₹cr)3533354139484440
EBITDA margin21.2%16.7%20.4%16.5%19.9%19.8%20.9%16.8%
PAT (₹cr)1614182020252333
↳ change QoQ—-14.4%+29.4%+9.6%+0.0%+25.0%-8.0%+43.5%
Net margin10.0%7.2%10.5%8.1%10.2%10.3%10.9%13.9%
EPS (₹)1.951.692.152.292.312.702.513.49
D/E————————
YoY growth · Mar '26Revenue -4.0% YoYPAT +65.0% YoY

Corporate announcements

Filings to the exchange — capital actions, earnings and governance. Most recent first.

  • 10 Sep '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 4 Sep '26
    LOWgovernance
    Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 4 Sep '26
    LOWgovernance
    Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 2 Sep '26
    MEDIUMcapital
    Credit Rating
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 27 Aug '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 6 Aug '26
    LOWgovernance
    Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 1 Aug '26
    MEDIUMearnings
    Investor Presentation
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 1 Aug '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 31 Jul '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 31 Jul '26
    LOWgovernance
    Change in Management
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 31 Jul '26
    LOWgovernance
    Integrated Filing- Financial
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 31 Jul '26
    HIGHearnings
    Outcome of Board Meeting
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 22 Jul '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 20 Jul '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 1 Jul '26
    LOWgovernance
    Spurt in Volume
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗

…and 5 more.

Ownership

Who holds SMSPHARMA

Mutual funds holding SMSPHARMA (1)

FundWeightAUM ₹crGrade
Quant Healthcare Reg Gr7.27%397

ETFs holding SMSPHARMA (0)

No tracked ETF holds SMSPHARMA ≥0.5%.

Show company profile (about, sector, employees, IPO)
Native from atlas_foundation — lens journal, technical_daily, ohlcv_stock; TradingView for the live instrument view. ← Back to Pharma